Ionis Pharmaceuticals Inc at Stifel CNS Day Transcript
Great. Thanks so much, everybody. It's my pleasure to be hosting this panel with Frank Bennett, an R&D leader at Ionis, and also one of the experts in neuroscience and neurology drug development. And he's been kind enough to join this conference every year. So I really appreciate it, Frank, for you coming today.
On that note, I was maybe just kind of hoping you could start, Frank, and give an overview of the various clinical-stage assets that Ionis has in development for CNS. And then naturally, we can get into Q&A and more of a discussion. So thanks again.
Well, my pleasure, and thank you for inviting me to participate. Yes, so we have a rich and growing pipeline of CNS drugs. To date, we have 2 approved drugs with -- and 9 drugs currently in clinical development, and a rich pipeline of preclinical drugs.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
